TY - JOUR
T1 - International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43
T2 - Phase IV
AU - on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups
AU - Singer, Susanne
AU - Amdal, Cecilie Delphin
AU - Hammerlid, Eva
AU - Tomaszewska, Iwona M.
AU - Castro Silva, Joaquim
AU - Mehanna, Hisham
AU - Santos, Marcos
AU - Inhestern, Johanna
AU - Brannan, Christine
AU - Yarom, Noam
AU - Fullerton, Amy
AU - Pinto, Monica
AU - Arraras, Juan I.
AU - Kiyota, Naomi
AU - Bonomo, Pierluigi
AU - Sherman, Allen C.
AU - Baumann, Ingo
AU - Galalae, Razvan
AU - Fernandez Gonzalez, Loreto
AU - Nicolatou-Galitis, Ourania
AU - Abdel-Hafeez, Zeinab
AU - Raber-Durlacher, Judith
AU - Schmalz, Claudia
AU - Zotti, Paola
AU - Boehm, Andreas
AU - Hofmeister, Dirk
AU - Krejovic Trivic, Sanja
AU - Loo, Suat
AU - Chie, Wei Chu
AU - Bjordal, Kristin
AU - Brokstad Herlofson, Bente
AU - Grégoire, Vincent
AU - Licitra, Lisa
N1 - Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2019/6
Y1 - 2019/6
N2 - Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
AB - Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
KW - chemoradiation
KW - head and neck cancer
KW - multimodal therapies
KW - quality of life
KW - validation
UR - http://www.scopus.com/inward/record.url?scp=85059916248&partnerID=8YFLogxK
U2 - 10.1002/hed.25609
DO - 10.1002/hed.25609
M3 - מאמר
C2 - 30636188
AN - SCOPUS:85059916248
VL - 41
SP - 1725
EP - 1737
JO - Head and Neck
JF - Head and Neck
SN - 1043-3074
IS - 6
ER -